<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830124</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 4230-006</org_study_id>
    <nct_id>NCT04830124</nct_id>
  </id_info>
  <brief_title>Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6</brief_title>
  <acronym>ARTISTRY-6</acronym>
  <official_title>A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in&#xD;
      patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Centrally-assessed overall response rate (ORR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug&#xD;
Response will be based on RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Centrally-assessed duration of response (DOR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-DOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally-assessed progression free survival (PFS)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-PFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally-assessed disease control rate (DCR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-DCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Centrally-assessed time to response (TTR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-TTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed overall response rate (ORR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed duration of response (DOR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-DOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed progression free survival (PFS)</measure>
    <time_frame>Up to 2 years from the first dose</time_frame>
    <description>-PFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed disease control rate (DCR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-DCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed time to response (TTR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-TTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed immune overall response rate (iORR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-iORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed immune duration of response (iDOR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-iDOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed immune progression free survival (iPFS)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-iPFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed immune disease control rate (iDCR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-iDCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed immune time to response (iTTR)</measure>
    <time_frame>Assessed up to 2 years from the first dose</time_frame>
    <description>-iTTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete or partial response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cutaneous Melanoma</condition>
  <condition>Mucosal Melanoma</condition>
  <arm_group>
    <arm_group_label>Advanced Cutaneous Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unresectable and/or metastatic cutaneous melanoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced mucosal melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unresectable and/or metastatic mucosal melanoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemvaleukin Alfa Subcutaneous</intervention_name>
    <description>Subcutaneous injection of nemvaleukin every 7 days</description>
    <arm_group_label>Advanced Cutaneous Melanoma</arm_group_label>
    <other_name>ALKS 4230 Subcutaneous</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemvaleukin Alfa Intravenous</intervention_name>
    <description>Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days</description>
    <arm_group_label>Advanced mucosal melanoma</arm_group_label>
    <other_name>ALKS 4230 Intravenous</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have advanced cutaneous melanoma or acral melanoma; no more than 5&#xD;
             patients with acral melanoma may enroll in this cohort (Cohort 1). Or, the patient&#xD;
             must have unresectable and/or metastatic mucosal melanoma (Cohort 2).&#xD;
&#xD;
          -  Patient must have received previous treatment as follows: a) patient has received&#xD;
             anti-PD-[L]1 therapy ± anti-CTLA-4 therapy, and ≤1 other prior regimen of systemic&#xD;
             anti-neoplastic therapy; b) patient should have experienced objective response (PR or&#xD;
             CR) or SD as BOR to anti-PD-[L]1 therapy; c) patients with BRAF mutations may or may&#xD;
             not have received prior targeted therapy.&#xD;
&#xD;
          -  Patients must have disease that is measurable based on RECIST 1.1., that has not&#xD;
             recently been irradiated or used to collect a biopsy.&#xD;
&#xD;
          -  Patient is willing to undergo a pretreatment tumor biopsy or provide qualifying&#xD;
             archival tumor tissue.&#xD;
&#xD;
          -  Patient has an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 and an&#xD;
             estimated life expectancy of ≥3 months.&#xD;
&#xD;
          -  Additional criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has uveal melanoma.&#xD;
&#xD;
          -  Patient has received prior IL-2-based or IL-15-based cytokine therapy.&#xD;
&#xD;
          -  Patient requires systemic corticosteroids (&gt;10 mg of prednisone daily, or equivalent)&#xD;
             however, replacement doses, topical, ophthalmologic, and inhalational steroids are&#xD;
             permitted.&#xD;
&#xD;
          -  Patient has undergone prior solid organ and/or non-autologous hematopoietic stem cell&#xD;
             or bone marrow transplant.&#xD;
&#xD;
          -  Patient is currently pregnant, breastfeeding, or is planning to become pregnant or to&#xD;
             begin breastfeeding during the study period or within 30 days after last study drug&#xD;
             administration.&#xD;
&#xD;
          -  Patients with active or symptomatic central nervous system metastases unless the&#xD;
             metastases have been treated by surgery and/or radiation therapy and/or gamma knife,&#xD;
             the subject has been tapered to a dose of 10 mg of prednisone (or equivalent) or less&#xD;
             of corticosteroids for at least 2 weeks before the first dose, and the subject is&#xD;
             neurologically stable. Patients with leptomeningeal disease are excluded.&#xD;
&#xD;
          -  Patient has known or suspected hypersensitivity to any components of nemvaleukin.&#xD;
&#xD;
          -  Patients with an uncontrollable bleeding disorder.&#xD;
&#xD;
          -  Patient has QT interval corrected by the Fridericia Correction Formula values of &gt;470&#xD;
             msec (in females) or &gt;450 msec (in males); patient who is known to have congenital&#xD;
             prolonged QT syndromes; or patient who is on medications known to cause prolonged QT&#xD;
             interval on ECG.&#xD;
&#xD;
          -  Patient has developed Grade ≥3 immune-related AEs (irAEs) while on prior&#xD;
             immunotherapy, (eg, pneumonitis, nephritis, and neuropathy).&#xD;
&#xD;
          -  Additional criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Mayo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>888-235-8008 (US Only)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>1-571-599-2702 (Global)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alkermes Investigator Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigator Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigator Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigator Site</name>
      <address>
        <city>Gangam-gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigator Site</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigator Site</name>
      <address>
        <city>Songpa-Gu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigator Site</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkermes</keyword>
  <keyword>ALKS 4230</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Nemvaleukin alfa</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interlukin-2</keyword>
  <keyword>Oncology</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Nemvaleukin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

